Still little developed in France, a minimally invasive procedure makes it possible to treat patients who were previously inoperable due to their age or fragile health.
Last October, a patient over 70 years old suffering from severe mitral regurgitation, and
who would not have been able to withstand conventional heart surgery, benefited from the implantation of a mitral bioprosthesis by catheter, called TendyneTM. It is a multidisciplinary team from the New Private Hospital Les Franciscaines, made up of cardiologists Eric Maupas and Victor-Xavier Tadros, Walid Ghodhbane, thoracic and cardiovascular surgeon and Dr Mathieu, cardiologist sonographer, who guided the entire procedure.
Still little developed in France, this cutting-edge minimally invasive technology “marks a decisive turning point in the care of patients who, due to their age or high surgical risk, are not eligible for traditional open-heart surgery”explains Walid Ghodhbane, thoracic and cardiovascular surgeon. “Valve replacement surgery is often the preferred treatment. TendyneTM offers a durable and less invasive alternative, suitable for these inoperable patients. adds Victor-Xavier Tadros.
Hope for high-risk patients
The installation of the TendyneTM bioprosthesis is a sophisticated procedure and less invasive than traditional surgery. In fact, it takes place without stopping the heart or resorting to circulation.
extracorporeal, which considerably reduces the surgical risks and complications
postoperative.
Mitral insufficiency, a pathology with multiple consequences
The mitral valve is one of the four valves of the heart that control the flow of blood. Mitral regurgitation is one of the most common heart valve diseases. It occurs when the mitral valve does not close properly, causing blood to leak in the opposite direction. This anomaly causes an overload of work for the heart which can lead to heart failure. Patients who suffer from it present varied symptoms: shortness of breath, chronic fatigue, dry or hacking cough, swollen ankles and feet, dizziness, etc.
Drug treatments can alleviate these symptoms but do not resolve the valve dysfunction causing the problem.
This technique is carried out by inserting a catheter through a small incision (approximately 3 cm) made in the thorax, between the ribs. The prosthesis is guided to the heart via the left ventricle, where it is deployed with pinpoint precision to replace the defective mitral valve.
1700 patients in France over the last six years
The procedure, carried out under general anesthesia, is guided in real time by Dr. Mathieu, a cardiologist and sonographer with advanced imaging techniques. The introduction of the catheter allows the prosthesis to be positioned and anchored directly in the native valve.
In France, the use of this TendyneTM bioprosthesis remains a niche medical area, with around 1,700 patients having benefited from it over the last six years.
With this new technique, the Franciscans “are pleased to be at the forefront of cutting-edge cardiac technologies.”
Health
Related News :